AnalystBook Research · Company Intelligence

Healthcare Triangle, Inc.

HCTINasdaq

Built from Healthcare Triangle, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score -8.14 distress zone — historically elevated failure riskWatch
  • Earnings-manipulation signal · Beneish M 0.61 flag raised, worth a closer lookWatch
  • Earnings quality 54/100 worth a closer lookWatch

Where the revenue comes from

Fiscal 2025, as Healthcare Triangle, Inc. reports it. History and quarterly detail are in the app.

  • Software Services$8.3M
  • Managed Services And Support$5.4M
  • Corporate Others$278K
  • Corporate And Others$278K

Leadership changes

From Healthcare Triangle, Inc.'s own filings, the day they're filed.

  • David Ayanoglou · Chief Financial Officer · appointmenteff. 2025-04-10
  • Thyagarajan Ramachandran · Chief Financial Officer · departureeff. 2025-04-10
  • David Ayanoglou · Chief Financial Officer · departureeff. 2025-04-10

Latest filings

  • 10-Q · Quarterly report2026-08-13
  • 8-K · Company announcement2026-07-29
  • 8-K · Company announcement2026-07-20
  • DEF 14A · Annual proxy (pay & governance)2026-06-26
  • 8-K · Company announcement2026-06-26
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Healthcare Triangle, Inc., every answer cited to the official filings🔒
  • The Intelligence Brief — added when Healthcare Triangle, Inc.'s brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.